Literature DB >> 18191309

Complement-HIV interactions during all steps of viral pathogenesis.

Heribert Stoiber1, Zoltan Banki, Doris Wilflingseder, Manfred P Dierich.   

Abstract

Upon crossing the endothelial barrier of the host, HIV initiates immediate responses of the immunity system. Among its components, the complement system is one of the first the first elements, which are activated to affect HIV propagation. Complement participates not only in the early phase of the immune response, but its effects can be observed continuously and also concern the induction and modification of the adaptive immune response. Here we discuss the role of complement in early and late stages of HIV pathogenesis and review the escape mechanisms, which protect HIV from destruction by the complement system.

Mesh:

Substances:

Year:  2007        PMID: 18191309     DOI: 10.1016/j.vaccine.2007.12.003

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  28 in total

1.  Impaired NK Cell Activation and Chemotaxis toward Dendritic Cells Exposed to Complement-Opsonized HIV-1.

Authors:  Rada Ellegård; Elisa Crisci; Jonas Andersson; Esaki M Shankar; Sofia Nyström; Jorma Hinkula; Marie Larsson
Journal:  J Immunol       Date:  2015-07-08       Impact factor: 5.422

Review 2.  Complement and HIV-I infection/HIV-associated neurocognitive disorders.

Authors:  Fengming Liu; Shen Dai; Jennifer Gordon; Xuebin Qin
Journal:  J Neurovirol       Date:  2014-03-18       Impact factor: 2.643

3.  Complement opsonization of HIV-1 results in decreased antiviral and inflammatory responses in immature dendritic cells via CR3.

Authors:  Rada Ellegård; Elisa Crisci; Adam Burgener; Christopher Sjöwall; Kenzie Birse; Garrett Westmacott; Jorma Hinkula; Jeffrey D Lifson; Marie Larsson
Journal:  J Immunol       Date:  2014-09-24       Impact factor: 5.422

Review 4.  Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?

Authors:  A Saez-Cirion; B Jacquelin; F Barré-Sinoussi; M Müller-Trutwin
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-05-12       Impact factor: 6.237

5.  A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS.

Authors:  Weiguo Hu; Qigui Yu; Ningjie Hu; Daniel Byrd; Tohti Amet; Cecilia Shikuma; Bruce Shiramizu; Jose A Halperin; Xuebin Qin
Journal:  J Immunol       Date:  2009-12-02       Impact factor: 5.422

6.  HIV gp41 engages gC1qR on CD4+ T cells to induce the expression of an NK ligand through the PIP3/H2O2 pathway.

Authors:  Hugues Fausther-Bovendo; Vincent Vieillard; Sandrine Sagan; Georges Bismuth; Patrice Debré
Journal:  PLoS Pathog       Date:  2010-07-01       Impact factor: 6.823

7.  Differential activity of candidate microbicides against early steps of HIV-1 infection upon complement virus opsonization.

Authors:  Mohammad-Ali Jenabian; Héla Saïdi; Charlotte Charpentier; Hicham Bouhlal; Dominique Schols; Jan Balzarini; Thomas W Bell; Guido Vanham; Laurent Bélec
Journal:  AIDS Res Ther       Date:  2010-06-14       Impact factor: 2.250

8.  HIV-1 fusion inhibitor peptides enfuvirtide and T-1249 interact with erythrocyte and lymphocyte membranes.

Authors:  Pedro M Matos; Miguel A R B Castanho; Nuno C Santos
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

9.  A new therapeutic strategy for lung tissue injury induced by influenza with CR2 targeting complement inhibitor.

Authors:  Chuanfu Zhang; Yuanyong Xu; Leili Jia; Yutao Yang; Yong Wang; Yansong Sun; Liuyu Huang; Fei Qiao; Stephen Tomlinson; Xuelin Liu; Yusen Zhou; Hongbin Song
Journal:  Virol J       Date:  2010-02-09       Impact factor: 4.099

10.  Human erythrocytes selectively bind and enrich infectious HIV-1 virions.

Authors:  Zoltan Beck; Bruce K Brown; Lindsay Wieczorek; Kristina K Peachman; Gary R Matyas; Victoria R Polonis; Mangala Rao; Carl R Alving
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.